5 New Diabetes Technologies and Treatments

Publication
Slideshow
Drug Topics JournalDrug Topics October 2019
Volume 163
Issue 10

Noteworthy diabetes management products and updates making waves this year.

Like other areas of healthcare, diabetes management in 2019 has been experiencing a combination of new device developments and improvements, technological advancements, new drug approvals, and new partnerships offering a glimpse of distant future possibilities. Here are five noteworthy products and updates that are making waves in the diabetes management space this year:

Download Issue PDF
Articles in this issue
statins heart rate
The Truth About Statins
color splash
Opinion: Color Coded Inhalers
tooth made out of pills
Pharmacist Collaborations Must Extend to Dentists
money in pill vial
Contemplating the Future of List Prices
New Drug Review: Tafamidis Meglumine for Cardiomyopathy
New Drug Review: Tafamidis Meglumine for Cardiomyopathy
genetics
Life-Altering Gene Therapy Pipeline Poses Challenges
empty pill bottles
Solving the Drug Shortage Burden
transgender hand with flag paint
Providing Healthcare to Transgender Patients
neon prep sign
State Laws May Determine Access to Pharmacy-based PrEP Clinics
Merger arrow
Official CVS/Aetna Merger: Greater Convenience, Less Cost Reform
Alternative Approaches to Opioids
Alternative Approaches to Opioids
diabetes
5 Types of Diabetes Patients Who Need More Management
5 New Diabetes Technologies and Treatments
5 New Diabetes Technologies and Treatments
woman holding stomach in pain
Lupus and Celiac Disease: What Pharmacists Need to Know
lefamulin product image
Lefamulin Could Be Vital in the Pneumonia Fight

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Subscribe Now!
Recent Videos
Image Credit: jokekung - stock.adobe.com
Image Credit: gamelover - stock.adobe.com
Related Content
SGLT-2 Inhibitors Decrease Risk of Serious Liver Events

SGLT-2 Inhibitors Decrease Risk of Serious Liver Events

Brian Nowosielski
July 28th 2025
Article

Among patients with cirrhosis receiving diuretic therapy, researchers explore the association between SGLT-2 inhibitors and the risk of serious liver outcomes.

The Evolving Landscape of Insulin Delivery in Diabetes Management

The Evolving Landscape of Insulin Delivery in Diabetes Management

Brian Nowosielski;Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES
July 17th 2025
Podcast

Amid increased advancements in diabetes management, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed how these developments are currently impacting the delivery of insulin.

FDA Approves Insulin Aspart-Xjhz as First Interchangeable Biosimilar to NovoLog

FDA Approves Insulin Aspart-Xjhz as First Interchangeable Biosimilar to NovoLog

Ashley Gallagher
July 21st 2025
Article

The FDA approves Kirsty, an interchangeable biosimilar insulin, enhancing diabetes treatment options and accessibility for patients.

Wicked Good Cardiometabolic Chat: Semaglutide’s Expanding Role in Chronic Disease

Wicked Good Cardiometabolic Chat: Semaglutide’s Expanding Role in Chronic Disease

Killian Meara;Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP;Hailey Choi, PharmD, BCACP, CDCES
July 15th 2025
Podcast

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

Q&A: Current Advancements in Insulin Delivery for Patients with Diabetes

Q&A: Current Advancements in Insulin Delivery for Patients with Diabetes

Brian Nowosielski;Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES
July 11th 2025
Article

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joins Drug Topics to discuss her extensive background in managing patients’ insulin regimens.

Q&A: The Challenges, Importance of Insulin Delivery for People with Diabetes

Q&A: The Challenges, Importance of Insulin Delivery for People with Diabetes

Brian Nowosielski;Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES
July 9th 2025
Article

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses the importance of insulin delivery and the common barriers pharmacists face in managing patients’ regimens.

© 2025 MJH Life Sciences

All rights reserved.